-
Sinogen’s SalMet-Vec Receives FDA Orphan Drug Designation for Pancreatic Cancer
•
China’s oncology specialist Guangzhou Sinogen Pharmaceutical Co., Ltd. has announced receiving Orphan Drug Designation (ODD) from the US FDA for its SalMet-Vec in pancreatic cancer. This oncolytic bacteria drug has previously earned ODD statuses from the agency for osteosarcoma, hepatocellular carcinoma, and small cell lung cancer. Drug Profile and MechanismSalMet-Vec…
-
Zai Lab and MediLink Therapeutics Partner to Develop LRRC15 ADC Drug ZL-6201 for Solid Tumors
•
On January 10, Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced a new strategic cooperation and global licensing agreement with MediLink Therapeutics. The partnership aims to utilize MediLink’s TMALIN® antibody-drug conjugate (ADC) platform to develop a novel LRRC15 ADC drug, ZL-6201, targeting solid tumors. The antibody for this product was…
-
Danaher Corporation Partners with Innovaccer to Enhance Healthcare AI Solutions
•
US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced an investment partnership with Innovaccer Inc., a leading Silicon Valley-based healthcare artificial intelligence (AI) company. The alliance is designed to improve patient prognosis and experience through innovative digital solutions. Innovaccer’s SolutionsInnovaccer offers a suite of software solutions designed…
-
Sanofi’s Sarclisa Meets Co-Primary Endpoints in Phase III IRAKLIA Study for Multiple Myeloma
•
French pharmaceutical giant Sanofi (NASDAQ: SNY, EPA: SAN) has announced that the Phase III IRAKLIA study for its Sarclisa (isatuximab) met its co-primary endpoints when administered subcutaneously (SC) via an on-body delivery system (OBDS) in patients with multiple myeloma (MM). This marks a significant step forward in the treatment of…
-
FDA Grants Priority Review to Johnson & Johnson’s Nipocalimab for Myasthenia Gravis
•
US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced that the US FDA has granted priority review status to the Biologics License Application (BLA) for its portfolio drug nipocalimab. This priority status is based on results from the Phase III Vivacity-MG3 study and is awarded for the product’s potential use…
-
Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio
•
German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from Synaffix B.V., a subsidiary of Switzerland’s Lonza (SWX: LONN). This strategic deal is expected to significantly enhance Boehringer’s ADC portfolio, driven by its subsidiary, NBE Therapeutics. Agreement DetailsUnder the terms of the agreement, Synaffix will…
-
Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments
•
UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co. (NYSE: LLY) to discover novel therapeutic candidates for the treatment of amyotrophic lateral sclerosis (ALS). This alliance is designed to accelerate the development of up to five new therapies for this debilitating condition. Agreement DetailsUnder…
-
Roche Gains FDA 510(k) Clearance for Roche Digital Pathology Dx with VENTANA DP 600
•
Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced an additional 510(k) clearance from the US FDA for its Roche Digital Pathology Dx, a whole slide imaging system that now includes the VENTANA DP 600 slide scanner. This clearance expands the capabilities of Roche’s digital pathology solutions, enhancing the diagnostic…
-
TCMTech Files for IPO on Hong Kong Stock Exchange, Showcasing TCM AI Leadership
•
China-based TCMTech Inc., recognized as the largest artificial intelligence (AI) empowered traditional Chinese medicine (TCM) medical service provider in its homeland in 2023, has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange. This move marks a significant step in the company’s growth and expansion strategy.…
-
Verdiva Bio Launches with USD 411 Million Series A Financing for Biopharma Development
•
UK-based Verdiva Bio Limited has announced its launch as a clinical-stage biopharma company, backed by an oversubscribed Series A financing of USD 411 million. The round was co-led by Forbion and General Atlantic, with additional investments from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital. Product…
-
ImmVira Partners with Merz Aesthetics to Develop Anti-Wrinkle Exosome Products
•
Shenzhen-based ImmVira’s exosomes-focused subsidiary has struck a partnership with US leading firm Merz Aesthetics. The collaboration is focused on the development of ImmVira’s engineered exosome anti-wrinkle products in the US and Canada. Partnership DetailsThe partnership aims to utilize ImmVira’s engineered exosome anti-wrinkle product as the core functional ingredient to upgrade…
-
SciWind Bio and Verdiva Bio Partner on Global Development of Obesity Therapies
•
On January 10, SciWind Bio announced a global development and commercialization license and collaboration agreement with Verdiva Bio, excluding Greater China and South Korea. Verdiva Bio is a clinical – stage global biopharmaceutical company focused on developing innovative therapies for obesity and other cardiovascular metabolic disorders. Collaboration DetailsThe collaboration includes…
-
MediLink and Zai Lab Collaborate on LRRC15-Targeted ADC Drug ZL-6201
•
Chinese biotechs MediLink Therapeutics (Suzhou) Co., Ltd and Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) have entered into a collaboration and license agreement. MediLink’s TMALIN antibody drug conjugate (ADC) platform will be utilized to develop ZL-6201, a novel LRRC15-targeted ADC drug discovered by Zai Lab, for the treatment of solid…
-
Bayer’s Elinzanetant Meets All Primary Endpoints in Phase III OASIS 4 Study
•
Germany-based Bayer AG (ETR: BAYN) has announced that the Phase III OASIS 4 study for its non-hormonal treatment elinzanetant has reached all primary endpoints. The study focused on moderate to severe vasomotor symptoms (VMS) caused by adjuvant endocrine therapy in women with breast cancer or at high risk of developing…
-
Inmagene Biopharmaceuticals Posts Positive Results for IMG-007 in Atopic Dermatitis
•
Inmagene Biopharmaceuticals, a Sino-US biotech that recently merged with US-based Ikena Oncology, Inc. (NASDAQ: IKNA), has posted additional positive topline results from the Phase IIa study for IMG-007 in patients with moderate-to-severe atopic dermatitis (AD). The company also released results from a Phase I trial of IMG-007’s subcutaneous (SC) formulation.…
-
BrainAurora Medical Technology IPOs on Hong Kong Stock Exchange
•
Zhejiang-based BrainAurora Medical Technology Limited (HKG: 6681), the first company in China to combine neuroscience and artificial intelligence (AI) technology for developing medical-grade digital therapy products, has successfully completed an initial public offering (IPO) of 181,112,000 shares on the Hong Kong Stock Exchange. The offering, priced at HKD 3.22 per…
-
Stryker to Acquire Inari Medical for USD 4.9 Billion to Boost VTE Pipeline
•
US-based Stryker (NYSE: SYK) has reached a definitive acquisition agreement with compatriot firm Inari Medical, Inc. (NASDAQ: NARI), purchasing all issued and outstanding shares at USD 80 per share in cash. The transaction amounts to a total fully diluted equity value of approximately USD 4.9 billion. Inari Medical’s PortfolioFounded in…
-
GSK Launches Cabotegravir Injection in China for HIV Pre-Exposure Prophylaxis
•
UK-based GlaxoSmithKline (GSK; NYSE: GSK) has announced the official commercial launch of its cabotegravir injection in China. The integrase strand transfer inhibitor (INSTI) was approved in May of last year for pre-exposure prophylaxis (PrEP) of HIV-1 in adults and adolescents (weighing ≥ 35kg) at risk of infection, to reduce the…
-
Insilico Medicine Raises USD 100 Million in Financing Round Led by Pudong and Hong Kong
•
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has reportedly raised USD 100 million in a new financing round. This marks the first joint investment effort between Shanghai’s Pudong district and Hong Kong in the biopharma sector. The initiative follows a partnership established in December 2023 between Shanghai Pudong Development…
-
Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS
•
Haier Biomedical (SHA: 688139) has announced the termination of its plan to acquire Shanghai RAAS (SHE: 002252), along with the associated share issuance for fundraising. The company cited the complex deal structure and the lack of a specific plan recognized by all parties involved as the reason for the termination,…
